Anti-IL-8 treatment regimens are currently in the clinical testing phase for non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) (NCT04123379, recruiting), and early (NCT01861054) and metastatic breast cancer (NCT02001974). The gene discussed is CXCL8; the disease is hepatocellular carcinoma.